BioElectronics Participates At 2017 Australian Pain Society

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
197
BioElectronics Participates At 2017 Australian Pain Society 37th Annual Scientific Meeting

FREDERICK, MD--(Marketwired - Apr 7, 2017) - BioElectronics Corporation ( OTC PINK : BIEL ), the maker of advanced noninvasive bioelectronic pain management medical devices, is pleased to announce that its devices are being featured at the 2017 Australian Pain Society 37th Annual Scientific Meeting, Sunday April 9th, 2017 - April 12th, 2017 http://www.dcconferences.com.au/aps2017/index.asp . The conference is focused on the basic science and treatment of pain for physicians, nurses, physical therapists, and researchers. The meeting participants include Mundipharma, Pfizer, GE Healthcare, Halyard, Abbott and leading Australian pain researchers.

BioElectronics' flagship product ActiPatch® Musculoskeletal Pain Therapy is a drug-free, wearable nonprescription medical device that provides 720-hours of on/off therapy to relieve chronic pain.

"We are making excellent progress in achieving product placement in our major pharmacy chains. This pain conference is an exceptional opportunity to create product awareness in the medical community," said Rob Gourlay of Evomed, the distributor of Actipatch in Australia and New Zealand. www. evomed .com.au

About BioElectronics Corporation BioElectronics Corporation is a leader in biophysics and the maker of ActiPatch® Therapy for back pain and other musculoskeletal complaints, RecoveryRx® Devices for chronic wounds and post-operative wound care, and Allay® Menstrual Pain Therapy. For clinical and more information, please visit www.bielcorp.com .

Contact: Paul Knopick 940.262.3584 pknopick@eandecommunications.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring Murphy Oil Inc.'s Price-to-Earnings Insights

Updated Category News Views 152

Understanding Murphy Oil Inc.'s Recent Market Performance Currently, Murphy Oil Inc. (NYSE: MUR) shares are valued at $30.88, exhibiting a minor rise of 0.06% in today's trading session. Observing the stock’s journey over the last month, we've seen a significant increase of 6.77%. However, when we take a closer look at the past year, the stock has unfortunately dropped...

Continue Reading
Marco Pharma: 35 Years of Principle Over Profits

Updated Category News Views 3

Keeping Principles Alive in a Competitive Market In an industry where folks often chase the latest trend like seagulls after a fish fry, Marco Pharma International stands its ground on principles rather than profits. It's rare to see a company, especially in the natural health sector, keeping its roots this deep for 35 years. And they're not just talking about it—this...

Continue Reading
Rakovina Therapeutics Unveils AI-Enhanced ATR Inhibitors Breakthrough

Updated Category News Views 188

Rakovina Therapeutics Presents AI-Developed ATR Inhibitors Rakovina Therapeutics Inc. (TSXV: RKV) has made a significant impact at a recent international conference dedicated to cancer therapeutics. The conference gathered numerous leaders in the field, creating an excellent platform to unveil groundbreaking research. Presenting their innovative findings, Rakovina...

Continue Reading
Elon Musk Critiques FCC's Denial of Starlink Subsidy While Aiding Disaster Recovery

Updated Category News Views 334

Elon Musk Critiques FCC's Decision on Starlink Subsidy Elon Musk, the visionary CEO of SpaceX, has voiced his discontent over the FCC's recent ruling that denied approximately $885 million in subsidies to Starlink, the company's satellite internet service. Musk described this decision as "contemptible political lawfare," coinciding with FEMA's deployment of Starlink...

Continue Reading
Assessing the Resilience of American Consumers Amid Challenges

Updated Category News Views 130

Understanding the Current Landscape of American Consumers The state of the American consumer remains resilient despite facing numerous challenges, as reported by Barclays in its recent analysis. The approach to consumer spending in the latest quarter reflects a balancing act, with buyers maneuvering through both advantageous conditions and potential obstacles. Positive...

Continue Reading